<unk>  is an antiviral medication that inhibits the replication of certain RNA viruses. It is used to treat COVID-19 in those infected by SARS-CoV-2.<unk>  is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine and exerts its antiviral action through introduction of copying errors during viral RNA replication.<unk>  was originally developed to treat influenza at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE), but was reportedly abandoned for mutagenicity concerns. It was then acquired by Miami-based company Ridgeback Biotherapeutics, which later partnered with Merck & Co. to develop the drug further. Based on positive results in placebo-controlled double-blind randomized clinical trials,<unk>  was approved for medical use in the United Kingdom in November 2021. In December 2021, the U.S. Food and Drug Administration (FDA) granted an emergency use authorization (EUA) to<unk>  for use in certain populations where other treatments are not feasible. The emergency use authorization was only narrowly approved (13-10) because of questions regarding efficacy and concerns that<unk> 's mutagenic effects could create new variants that evade immunity and prolong the COVID-19 pandemic.
Molnupiravir
Balapiravir
Odalasvir
Saquinavir
Remdesivir
Coronavir
Favipiravir
Maribavir